PLEKHO2

Across TCGA pan-cancer cohorts, PLEKHO2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLEKHO2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PLEKHO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLEKHO2 expression acts as an unfavorable survival marker.

COAD, GBM, and PDAC are the cancer types where PLEKHO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	II,III,IV	0.850	1.000	.033	18	view →
GBM	OS	Quartile	All	0.374	0.755	.001	13	view →
PDAC	OS	Tertile	II,III,IV	0.718	1.000	.002	7	view →
LUAD	OS	Median	III,IV	0.435	0.777	.007	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLEKHO2–COAD (DFS)

Open the COAD breakdown →